PETROS PHARMACEUTICALS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6399 USD | 0.00% |
|
-4.51% | -54.62% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 4.825 | 3.104 | 4.4 | - | - |
| Enterprise Value (EV) 1 | 4.825 | 3.104 | 4.4 | 4.4 | 4.4 |
| P/E ratio | -0.24 x | -0.22 x | -0.11 x | -0.15 x | -0.2 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 0.53 x | 0.78 x | 0.78 x | 0.39 x |
| EV / Revenue | - | 0.53 x | 0.78 x | 0.78 x | 0.39 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | -0.74 x | -0.66 x | -0.96 x |
| FCF Yield | - | - | -135% | -153% | -104% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,071 | 2,201 | 6,876 | - | - |
| Reference price 2 | 2.330 | 1.410 | 0.6399 | 0.6399 | 0.6399 |
| Announcement Date | 3/31/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 5.822 | 5.665 | 5.67 | 11.22 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -13.62 | -12.17 | -12.72 | -9.263 |
| Operating Margin | - | -233.88% | -214.85% | -224.32% | -82.52% |
| Earnings before Tax (EBT) 1 | - | -8.163 | -12.78 | -13.33 | -9.875 |
| Net income 1 | -20.04 | -8.163 | -12.78 | -13.33 | -9.875 |
| Net margin | - | -140.2% | -225.65% | -235.11% | -87.97% |
| EPS 2 | -9.680 | -6.350 | -6.010 | -4.250 | -3.140 |
| Free Cash Flow 1 | - | - | -5.955 | -6.717 | -4.59 |
| FCF margin | - | - | -105.12% | -118.47% | -40.89% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/31/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|
| Net sales 1 | 1.454 | 1.429 | 1.404 | 1.379 |
| EBITDA | - | - | - | - |
| EBIT 1 | -2.9 | -2.994 | -3.09 | -3.188 |
| Operating Margin | -199.45% | -209.52% | -220.09% | -231.18% |
| Earnings before Tax (EBT) 1 | -3.053 | -3.147 | -3.243 | -3.341 |
| Net income 1 | -3.053 | -3.147 | -3.243 | -3.341 |
| Net margin | -209.97% | -220.22% | -230.98% | -242.28% |
| EPS 2 | -1.440 | -1.480 | -1.520 | -1.570 |
| Dividend per Share | - | - | - | - |
| Announcement Date | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -5.96 | -6.72 | -4.59 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/31/23 | 4/1/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.6399
USD
Average target price
4
USD
Spread / Average Target
+525.10%
EPS Revisions
- Stock Market
- Equities
- PTPI Stock
- Financials Petros Pharmaceuticals
